Subscribe to the newsletter

Publication — IRIC

Targeting copper metabolism to defeat KRAS-driven colorectal cancer.

KRAS-driven cancers acquire profound metabolic dependencies that are intimately linked to tumor growth. Our work revealed that colorectal cancers that harbor KRAS mutations are addicted to copper metabolism. This adaptation renders tumor cells critically dependent on the copper transporter ATP7A, which reveals copper metabolism as a promising therapeutic target for KRAS-driven colorectal cancers.

Publication date
October 7, 2020
Principal Investigators
Aubert L, Nandagopal N, Roux PP
PubMed reference
Mol Cell Oncol 2020;7(6):1822123
PubMed ID
33235918
Affiliation
Institute for Research in Immunology and Cancer (IRIC), Université De Montréal, Montreal, Quebec, Canada.